Who ChondroFiller injection is for

The short answer is that ChondroFiller injection is broadly inclusive. Any adult with articular cartilage damage visible on imaging — whether a contained focal lesion or wear spread across a joint surface — is considered a potential candidate. There is no upper age limit on the injectable route, and no defect-size ceiling that automatically rules it out.

The strongest positive signals are MRI-confirmed cartilage damage across any joint: knee, hip, ankle, shoulder, elbow, wrist, or the smaller hand and thumb joints. Post-traumatic lesions — including osteochondritis dissecans (OCD) and damage associated with prior meniscal injury — sit well within that picture. So do patients in their 60s, 70s, and beyond who want to preserve their own joint before considering replacement; the injectable collagen scaffold is specifically relevant in this group, where conventional surgical alternatives carry greater risk and the window for biological repair is narrowing.

Candidacy is not, however, a self-assessment process. MRI imaging establishes the grade, extent, and pattern of damage, and it is that imaging — reviewed at a consultant appointment — that determines whether the ChondroFiller injection is the right approach or whether another pathway would serve the patient better first. The factors that might modify or defer the plan are part of that clinical assessment, covered in a later section.

What MRI reveals about your cartilage damage

The MRI scan does more than confirm that cartilage damage is present — it defines the clinical picture that shapes every subsequent decision.

Three things matter most. The first is depth of damage, measured using the International Cartilage Repair Society (ICRS) grading system. Grade 2 describes a lesion that has eroded less than half the cartilage thickness; Grade 3 means more than half the depth is lost, with sub-grades that reflect whether the damage has reached the calcified layer immediately above the bone; Grade 4 is full-thickness loss, with the subchondral bone itself exposed. These grades are not simply labels — they indicate how much viable cartilage architecture remains and which biological interventions are still feasible.

The second factor is defect area. Around 2–4 cm² is where clinical pathways tend to diverge: lesions below that threshold may respond to simpler approaches, while defects at or above it generally call for a scaffold or cell-based option such as ChondroFiller injection to provide meaningful structural support.

The third is pattern — whether damage is focal and contained within a defined boundary, or diffuse across the joint surface. That distinction has direct bearing on whether ChondroFiller injection alone is the appropriate route or whether additional structural workup is warranted first.

At follow-up, two scoring systems provide semi-quantitative benchmarks. MOAKS gives a whole-joint assessment useful at baseline; MOCART evaluates how well repair tissue has filled a treated defect on post-treatment imaging — published MOCART scores of 70–87 following ChondroFiller injection serve as a structural reference point for monitoring recovery over time.

The assessment pathway from first enquiry to treatment

Getting from first question to treatment involves four straightforward stages, each with a defined purpose.

Step 1 — Discovery call (15 minutes, free). A clinical coordinator speaks with the patient to understand the history, check that appropriate imaging is in place or obtainable, and confirm that a full consultant consultation makes sense. This is pre-screening, not a clinical assessment.

Step 2 — Consultant consultation (one hour). Professor Paul Lee reviews the MRI, maps the cartilage defect in detail, and discusses the full range of relevant options. By the end of the appointment, a written treatment plan has been agreed — there is no pressure to decide on the day.

Step 3 — ChondroFiller injection (30–45 minutes). The injection is an outpatient procedure carried out under local anaesthesia using real-time ultrasound guidance. No general anaesthetic is needed and no hospital admission is required. Patients typically leave the clinic on the same day.

Step 4 — Six-week follow-up. A structured review at six weeks is included within the treatment pathway, allowing progress to be assessed and any questions addressed.

For patients travelling from abroad, the pathway can be condensed so that consultation, imaging review, and treatment all take place during a single visit to the London Cartilage Clinic on Harley Street, minimising disruption for those who cannot make multiple trips to London.

When other issues need to be resolved first

Some presentations call for structural workup before the cartilage pathway becomes the right conversation. This is sequencing, not disqualification — many patients with the issues below are still candidates once the underlying problem is addressed.

Ligament instability is the clearest example. A joint that is mechanically unstable cannot provide the stable environment a collagen scaffold needs in order to integrate and function. Reconstructing the relevant ligament first is essential; ChondroFiller injection can follow once joint mechanics are sound.

Significant malalignment — a pronounced varus (bow-leg) or valgus (knock-knee) deformity — concentrates load onto one compartment in ways an injection cannot counteract. An osteotomy or alignment procedure may need to precede or accompany cartilage treatment; without it, focussed loading is likely to overwhelm repair tissue before it matures.

Meniscal deficiency that is the primary driver of cartilage wear requires its own assessment. Where the meniscus is the dominant cause of ongoing damage, treating the cartilage surface first is unlikely to produce durable results.

Diffuse Kellgren-Lawrence Grade III or IV osteoarthritis sits in a different category: it does not exclude ChondroFiller injection, but the joint environment as a whole may need addressing alongside the cartilage surfaces. In those cases, Arthrosamid — a non-regenerative polyacrylamide hydrogel injected into the synovium to cushion and reduce mechanical load — may be used alongside ChondroFiller injection. The two products serve different roles: Arthrosamid manages the joint space; ChondroFiller injection supports cartilage repair at the bone surface. They should not be treated as the same type of treatment.

For patients with very advanced wear, autologous MSC augmentation may be considered to strengthen the cellular environment for scaffold integration. This is appropriate for a small subset of cases and is assessed individually at consultation.

Outcomes and how repair is monitored over time

Published case series across more than 19,000 global ChondroFiller treatments report a complaint rate of approximately 0.06% and a reoperation rate of around 3–8%. Functional outcomes follow a consistent pattern: IKDC scores improve by approximately 30 points in the knee; modified Harris Hip Score gains reach around 30–33 points in the hip — clinically significant shifts that reflect patients recovering function rather than achieving marginal relief.

Post-treatment MRI provides the structural counterpart. Published studies show reduction in bone marrow oedema, diminished periarticular effusion, and visible joint-space widening — markers that confirm scaffold-supported tissue change, not symptom suppression alone. MOCART imaging scores of 70–87 are the reported benchmark for cartilage repair quality.

Those 19,000 cases, and the functional and MRI outcomes they underpin, relate to ChondroFiller injection as a standalone treatment. The combined NanoACi three-part protocol — ChondroFiller injection, Arthrosamid, and autologous MSCs — does not yet have randomised controlled trial data as a combined package. Each component carries its own published evidence, but the additive benefit of layering all three has not been established in a controlled study. The clinical rationale draws on distinct mechanisms for each product; the RCT evidence is component-level rather than protocol-level.

Monitoring continues after treatment through annual MRI review, annual peptide support, and bi-annual ChondroFiller top-up injections — a long-term programme aimed at preserving joint integrity over years rather than managing a single episode of wear.

Starting your assessment at the London Cartilage Clinic

ChondroFiller injection is available in the UK through the London Cartilage Clinic on Harley Street — the UK's certified delivery centre for the product. Assessment begins with a free 15-minute discovery call, during which a clinical coordinator confirms whether an MRI-led consultation is the appropriate next step. There is no obligation to proceed beyond that call.

The formal consultation is led by Professor Paul Y. F. Lee, who oversees the image-guided placement of the scaffold. Precision in delivery matters: how and where the collagen is introduced affects how the matrix integrates and how well the body responds.

For patients coming from outside London, the pathway can be condensed — consultation, imaging review, and injection on the same visit where clinically appropriate.

To arrange a discovery call or book a consultation, visit londoncartilage.com.